66191-86-4

Basic information

• Product Name: methyl 3-(2-bromophenyl)propanoate
• Synonyms: methyl 3-(2-bromophenyl)propanoate;Methyl 3-(2-bromophenyl)propionate;O-broMophenolMethyl propionate
• CAS NO: 66191-86-4
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.1
• Mol File: 66191-86-4.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 87℃/0.02Torr
• Flash Point: 124.944 °C
• Appearance: Colorless to pale yellow/Liquid
• Density: 1.39 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.5380 to 1.5420
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl 3-(2-bromophenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(2-bromophenyl)propanoate(66191-86-4)
• EPA Substance Registry System: methyl 3-(2-bromophenyl)propanoate(66191-86-4)

Safety Data

• Hazardous Substances Data: 66191-86-4(Hazardous Substances Data)

Usage

General Description

Methyl 3-(2-bromophenyl)propanoate is a chemical compound that belongs to the class of organic compounds known as benzoic acids and derivatives. It is a derivative of benzoic acid, containing a 3-(2-bromophenyl)propanoate moiety. methyl 3-(2-bromophenyl)propanoate is a colorless liquid, commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the production of fragrances and as a flavoring agent in the food industry. Additionally, it has potential applications in organic synthesis and chemical research. However, as a halogenated compound, it should be handled with care, due to its potential environmental and health hazards.

InChI:InChI=1/C10H11BrO2/c1-13-10(12)7-6-8-4-2-3-5-9(8)11/h2-5H,6-7H2,1H3

Upstream product

• 15115-58-9 3-(2-bromophenyl)propionic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 23600-76-2 2-bromophenyl propionic acid 
• 58380-12-4 <(2-bromophenyl)methyl>propanedicarboxylic acid 
• 1160998-28-6 2-(2-bromo-benzylidene)-malonic acid dimethyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 6630-33-7 ortho-bromobenzaldehyde 
• 90725-40-9 3-(2-bromophenyl)propanoyl chloride 
• 201230-82-2 carbon monoxide 
• 2039-88-5 2-bromostyrene 

Downstream Products

• 946084-16-8 C₁₁H₁₂O₂ 
• 195969-54-1 methyl 3-(2-vinylphenyl)propanoate 
• 946083-88-1 C₁₉H₂₆O₂ 
• 946083-91-6 C₁₇H₂₂O₄ 
• 283173-11-5 3-[2-(6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)-phenyl]-propionic acid methyl ester 
• 1358579-18-6 5-(2-bromophenyl)-1-phenylpentane-1,3-diketone 
• 119225-99-9 1-phenyl-2-((2Z)-1,2,3,4-tetrahydroquinolin-2-ylidene)ethan-1-one 
• 1170060-01-1 1-(3,4-dimethoxyphenyl)-2-[(2Z)-1,2,3,4-tetrahydroquinolin-2-ylidene]ethan-1-one 

Relevant articles and documents

Reduction of Electron-Deficient Alkenes Enabled by a Photoinduced Hydrogen Atom Transfer

Direct hydrogen atom transfer from a photoredox-generated Hantzsch ester radical cation to electron-deficient alkenes has enabled the development of an efficient formal hydrogenation under mild, operationally simple conditions. The HAT-driven mechanism is supported by experimental and computational studies. The reaction is applied to a variety of cinnamate derivatives and related structures, irrespective of the presence of electron-donating or electron-withdrawing substituents in the aromatic ring and with good functional group compatibility. (Figure presented.).

Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors

WAY-267,464 (1) and twelve conformationally rigid analogues (3a-f–4a-f) were synthesised, characterised and evaluated in cellular assays with the aim of systematically exploring interactions with the oxytocin receptor (OTR). Each analogue was evaluated in

1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS

The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formulawherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.